Effects of mean platelet volume levels on the platelet reactivity and clinical prognosis of patients with coronary stent implantation undergoing ticagrelor
Sun Yujia
Zhao Dechao
Abstract：Objective To investigate the effect of mean platelet volume(MPV)level on platelet reactivity and clinical outcome under the action of ticagrelor.Methods From August 2019 to October 2020,192 patients with acute coronary syndrome(ACS)who underwent percutaneous coronary intervention(PCI)and were treated with ticagrelor in the First Affiliated Hospital of Harbin Medical University were divided into low MPV group(n=90,MPV＜10.2 fl)and high MPV group(n=102,MPV≥10.2 fl).Before the operation,all patients were given a loaded dose of aspirin(300 mg)and ticagrelor(180 mg).Subsequently,maintenance doses of aspirin(100 mg/d)and ticagrelor(90 mg/d)were given.A thromboelastogram was used to detect the platelet inhibition rate of each group after taking medicine for one week.After 12 months of the dual antiplatelet therapy(DAPT)regimen,ticagrelor was stopped,and aspirin(100 mg/d)was continued.Major adverse cardiovascular events(MACE)were followed up for 24 months to compare clinical efficacy.Results After 24 months of follow-up,there was no significant difference in the total incidence of MACE between the two groups(P>0.05).There was no significant difference in the incidence of MACE between the two groups with DAPT(P>0.05).The incidence of MACE was statistically substantial when aspirin alone was used(P＜0.05).The ROC curve area of MPV that predicts MACE in patients with aspirin alone was 0.664(95%CI:0.538～0.749,P=0.032).Conclusion MPV level does not affect platelet responsiveness with ticagrelor,and the incidence of MACE increases in patients with high MPV after discontinuation of ticagrelor.
Keywords：Acute coronary syndromePercutaneous coronary interventionMean platelet volumeTicagrelor
Publication Date：2023-12-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1338-1341 )